opentargets/clinical_trial_reason_to_stop · Datasets at Hugging Face

text stringlengths 4 164	label_descriptions sequence	Another_Study bool 2 classes	Business_Administrative bool 2 classes	Covid19 bool 2 classes	Endpoint_Met bool 2 classes	Ethical_Reason bool 2 classes	Insufficient_Data bool 2 classes	Insufficient_Enrollment bool 2 classes	Interim_Analysis bool 2 classes	Invalid_Reason bool 2 classes	Logistics_Resources bool 2 classes	Negative bool 2 classes	No_Context bool 2 classes	Regulatory bool 2 classes	Safety_Sideeffects bool 2 classes	Study_Design bool 2 classes	Study_Staff_Moved bool 2 classes	Success bool 2 classes
Business considerations in light of slow enrollment.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Business decision	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Business decision related to efficacy rather than tolerability limitations, not stopped for anyÊ safety reasons.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Business decision to end program	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Business decision to stop the program	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Business decision.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Business decision. No patients were enrolled	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Business decision. Study never started	[ "Business_Administrative", "Invalid_Reason" ]	false	true	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false
Business development reasons.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Business objectives changed.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Business reasons	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
CDC's decision to down-select vaccine development to single candidate, ACAM2000"	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
CO Phase 2 data did not show sufficient improvement in cath opening at higher dose/concentration evaluated. Nuvelo ended further clinical dev of alfimeprase.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
COVID -19 HOLD	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
COVID 19 outbreak	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
COVID-19	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
COVID-19 HOLD	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
COVID-19 Hold	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
COVID-19 Pandemic	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
COVID-19 Pandemic Measures	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
COVID-19 outbreak	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
COVID-19 outbreak, we have decided to discontinue the study.	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
COVID-19 pandemic	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
COVID-19 pandemic.	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
COVID-19 precautions	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
COVID-19 restrictions	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
COVID-19 social distancing requirements	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
COVID-19; Temporary suspension of non-essential human subjects research	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
COVID19	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
COVID19 Suspension	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
COVID19-pandemic- Need to minimize exposure. Effects of steroids on COVID19 positive patients	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Cancelled Before Enrollment	[ "Invalid_Reason" ]	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false
Cancelled before enrollment	[ "Invalid_Reason" ]	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false
Cancelled before first patient enrolled	[ "Invalid_Reason" ]	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false
Carisbamate partial onset seizures studies lacked consistent efficacy data so trials in this indication were terminated.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Ceased production of the study drug, Lymphoglobulin. Recruitment of patients onto the trialÊ was too slow.	[ "Logistics_Resources", "Insufficient_Enrollment", "Study_Design" ]	false	false	false	false	false	false	true	false	false	true	false	false	false	false	true	false	false
Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All Celgene-sponsored trials with MGCD0103 will be closed.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All Celgene-sponsored trials with MGCD0103 with be closed.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Celgene unable to continue funds.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Challenging data collection	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Change company strategy	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Change development strategy	[ "Logistics_Resources", "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Change in Belgian law on the use of hMG in IUI	[ "Regulatory" ]	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false
Change in Formulation	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Change in available resources for study procedures	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Change in company direction	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Change in company strategy	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Change in drug product development strategy	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Change in formulation	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Change in institutional headquarters for the US study.	[ "Study_Staff_Moved" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false
Change in isolation method	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Change in patient population no longer fit study criteria.	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Change in strategy regarding the product by the company	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Change in strategy.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Change in the development plan for the anti-OX40 antibody.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Change in the procedure of cells infusion to be approved by the regulatory authority.	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Change in treatment priorities for these disease types as well as staffing concerns.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Change of MRI mode	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Change of dose regimen (new protocol)	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Change of practice in the department	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Change of practice pattern. Green light laser	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Change of research focus	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Change of staff	[ "Study_Staff_Moved" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false
Change of study population and chemotherapeutic regimen	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Change the sample size due to smaller variance than expected	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Change to investigator's research affiliation and other employment.	[ "Study_Staff_Moved" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false
Changes & upgrades in informatic infrastructure of the web-based intervention.	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Changes in practice	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Changes in treatment paradigm resulted in a lower than expected rate of accrual.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Changes of SoC for third line therapy resulting in poor recruitment	[ "Insufficient_Enrollment", "Study_Design" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	true	false	false
Choice of the principal investigator	[ "Insufficient_Data" ]	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false	false
Clearly identifiable benefits 50% of patients included	[ "Success" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true
Clinical Hold	[ "Invalid_Reason", "Regulatory" ]	false	false	false	false	false	false	false	false	true	false	false	false	true	false	false	false	false
Clinical Hold pending additional data review and protocol amendment	[ "Study_Design", "Interim_Analysis" ]	false	false	false	false	false	false	false	true	false	false	false	false	false	false	true	false	false
Clinical Hold- product related issue	[ "Regulatory" ]	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false
Clinical Team decision to terminate the study after the results from Cohort 1 did not supportÊ conducting Cohort 2.	[ "Endpoint_Met", "Negative" ]	false	false	false	true	false	false	false	false	false	false	true	false	false	false	false	false	false
Clinical partner left University,"	[ "Study_Staff_Moved" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false
Clinicians were not offering the study to eligible potential subjects.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Closed due prolonged enrollment timelines	[ "Insufficient_Enrollment", "Study_Design" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	true	false	false
Closed due to delay by GSK	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Closed due to futility with only 1 patient accrued	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Closed due to insufficient recruitment	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Closed due to insufficient recruitment.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Closed due to lack of enrollment	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Closed due to poor accrual.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Closed due to slow accrual	[ "Logistics_Resources", "Business_Administrative", "Insufficient_Enrollment" ]	false	true	false	false	false	false	true	false	false	true	false	false	false	false	false	false	false
Closed due to slowing enrollment and negative results of a phase III trial using cabozantinib.	[ "Insufficient_Enrollment", "Another_Study" ]	true	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Closed early due to poor accrual.	[ "Insufficient_Enrollment", "Insufficient_Data" ]	false	false	false	false	false	true	true	false	false	false	false	false	false	false	false	false	false
Closed for lack of enrollment	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Closed to Accrual	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Closed to accrual in March 2009 for slow accrual.	[ "Business_Administrative", "Logistics_Resources" ]	false	true	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Closed, never started."	[ "Invalid_Reason" ]	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false
Closure of Indiana University Health Proton Center in December 2014	[ "Study_Staff_Moved" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false
Closures due to COVID-19	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
CoStar Stent IDE failed to meet primary endpoint	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Collaboration could not be established	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Collaborator no longer interested, short of funds"	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Collected study data was not usable due to process miscommunications	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Combination of departure of Investigator from one site and slow recruitment rate	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Comflicting interim data	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false

Business considerations in light of slow enrollment.

[ "Business_Administrative" ]

false

true

false

Business decision

[ "Business_Administrative" ]

false

true

false

Business decision related to efficacy rather than tolerability limitations, not stopped for anyÊ safety reasons.

[ "Business_Administrative" ]

false

true

false

Business decision to end program

[ "Business_Administrative" ]

false

true

false

Business decision to stop the program

[ "Business_Administrative" ]

false

true

false

Business decision.

[ "Business_Administrative" ]

false

true

false

Business decision. No patients were enrolled

[ "Business_Administrative" ]

false

true

false

Business decision. Study never started

[ "Business_Administrative", "Invalid_Reason" ]

false

true

false

true

false

Business development reasons.

[ "Business_Administrative" ]

false

true

false

Business objectives changed.

[ "Business_Administrative" ]

false

true

false

Business reasons

[ "Business_Administrative" ]

false

true

false

CDC's decision to down-select vaccine development to single candidate, ACAM2000"

[ "Business_Administrative" ]

false

true

false

CO Phase 2 data did not show sufficient improvement in cath opening at higher dose/concentration evaluated. Nuvelo ended further clinical dev of alfimeprase.

[ "Negative" ]

false

true

false

COVID -19 HOLD

[ "Covid19" ]

false

true

false

COVID 19 outbreak

[ "Covid19" ]

false

true

false

COVID-19

[ "Covid19" ]

false

true

false

COVID-19 HOLD

[ "Covid19" ]

false

true

false

COVID-19 Hold

[ "Covid19" ]

false

true

false

COVID-19 Pandemic

[ "Covid19" ]

false

true

false

COVID-19 Pandemic Measures

[ "Covid19" ]

false

true

false

COVID-19 outbreak

[ "Covid19" ]

false

true

false

COVID-19 outbreak, we have decided to discontinue the study.

[ "Covid19" ]

false

true

false

COVID-19 pandemic

[ "Covid19" ]

false

true

false

COVID-19 pandemic.

[ "Covid19" ]

false

true

false

COVID-19 precautions

[ "Covid19" ]

false

true

false

COVID-19 restrictions

[ "Covid19" ]

false

true

false

COVID-19 social distancing requirements

[ "Covid19" ]

false

true

false

COVID-19; Temporary suspension of non-essential human subjects research

[ "Covid19" ]

false

true

false

COVID19

[ "Covid19" ]

false

true

false

COVID19 Suspension

[ "Covid19" ]

false

true

false

COVID19-pandemic- Need to minimize exposure. Effects of steroids on COVID19 positive patients

[ "Covid19" ]

false

true

false

Cancelled Before Enrollment

[ "Invalid_Reason" ]

false

true

false

Cancelled before enrollment

[ "Invalid_Reason" ]

false

true

false

Cancelled before first patient enrolled

[ "Invalid_Reason" ]

false

true

false

Carisbamate partial onset seizures studies lacked consistent efficacy data so trials in this indication were terminated.

[ "Negative" ]

false

true

false

Ceased production of the study drug, Lymphoglobulin. Recruitment of patients onto the trialÊ was too slow.

[ "Logistics_Resources", "Insufficient_Enrollment", "Study_Design" ]

false

true

false

true

false

true

false

Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All Celgene-sponsored trials with MGCD0103 will be closed.

[ "Business_Administrative" ]

false

true

false

Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All Celgene-sponsored trials with MGCD0103 with be closed.

[ "Business_Administrative" ]

false

true

false

Celgene unable to continue funds.

[ "Business_Administrative" ]

false

true

false

Challenging data collection

[ "Logistics_Resources" ]

false

true

false

Change company strategy

[ "Business_Administrative" ]

false

true

false

Change development strategy

[ "Logistics_Resources", "Business_Administrative" ]

false

true

false

true

false

Change in Belgian law on the use of hMG in IUI

[ "Regulatory" ]

false

true

false

Change in Formulation

[ "Study_Design" ]

false

true

false

Change in available resources for study procedures

[ "Logistics_Resources" ]

false

true

false

Change in company direction

[ "Business_Administrative" ]

false

true

false

Change in company strategy

[ "Business_Administrative" ]

false

true

false

Change in drug product development strategy

[ "Business_Administrative" ]

false

true

false

Change in formulation

[ "Study_Design" ]

false

true

false

Change in institutional headquarters for the US study.

[ "Study_Staff_Moved" ]

false

true

false

Change in isolation method

[ "Study_Design" ]

false

true

false

Change in patient population no longer fit study criteria.

[ "Study_Design" ]

false

true

false

Change in strategy regarding the product by the company

[ "Business_Administrative" ]

false

true

false

Change in strategy.

[ "Business_Administrative" ]

false

true

false

Change in the development plan for the anti-OX40 antibody.

[ "Business_Administrative" ]

false

true

false

Change in the procedure of cells infusion to be approved by the regulatory authority.

[ "Study_Design" ]

false

true

false

Change in treatment priorities for these disease types as well as staffing concerns.

[ "Business_Administrative" ]

false

true

false

Change of MRI mode

[ "Study_Design" ]

false

true

false

Change of dose regimen (new protocol)

[ "Study_Design" ]

false

true

false

Change of practice in the department

[ "Study_Design" ]

false

true

false

Change of practice pattern. Green light laser

[ "Study_Design" ]

false

true

false

Change of research focus

[ "Business_Administrative" ]

false

true

false

Change of staff

[ "Study_Staff_Moved" ]

false

true

false

Change of study population and chemotherapeutic regimen

[ "Study_Design" ]

false

true

false

Change the sample size due to smaller variance than expected

[ "Negative" ]

false

true

false

Change to investigator's research affiliation and other employment.

[ "Study_Staff_Moved" ]

false

true

false

Changes & upgrades in informatic infrastructure of the web-based intervention.

[ "Logistics_Resources" ]

false

true

false

Changes in practice

[ "Study_Design" ]

false

true

false

Changes in treatment paradigm resulted in a lower than expected rate of accrual.

[ "Insufficient_Enrollment" ]

false

true

false

Changes of SoC for third line therapy resulting in poor recruitment

[ "Insufficient_Enrollment", "Study_Design" ]

false

true

false

true

false

Choice of the principal investigator

[ "Insufficient_Data" ]

false

true

false

Clearly identifiable benefits 50% of patients included

[ "Success" ]

false

true

Clinical Hold

[ "Invalid_Reason", "Regulatory" ]

false

true

false

true

false

Clinical Hold pending additional data review and protocol amendment

[ "Study_Design", "Interim_Analysis" ]

false

true

false

true

false

Clinical Hold- product related issue

[ "Regulatory" ]

false

true

false

Clinical Team decision to terminate the study after the results from Cohort 1 did not supportÊ conducting Cohort 2.

[ "Endpoint_Met", "Negative" ]

false

true

false

true

false

Clinical partner left University,"

[ "Study_Staff_Moved" ]

false

true

false

Clinicians were not offering the study to eligible potential subjects.

[ "Insufficient_Enrollment" ]

false

true

false

Closed due prolonged enrollment timelines

[ "Insufficient_Enrollment", "Study_Design" ]

false

true

false

true

false

Closed due to delay by GSK

[ "Business_Administrative" ]

false

true

false

Closed due to futility with only 1 patient accrued

[ "Insufficient_Enrollment" ]

false

true

false

Closed due to insufficient recruitment

[ "Insufficient_Enrollment" ]

false

true

false

Closed due to insufficient recruitment.

[ "Insufficient_Enrollment" ]

false

true

false

Closed due to lack of enrollment

[ "Insufficient_Enrollment" ]

false

true

false

Closed due to poor accrual.

[ "Insufficient_Enrollment" ]

false

true

false

Closed due to slow accrual

[ "Logistics_Resources", "Business_Administrative", "Insufficient_Enrollment" ]

false

true

false

true

false

true

false

Closed due to slowing enrollment and negative results of a phase III trial using cabozantinib.

[ "Insufficient_Enrollment", "Another_Study" ]

true

false

true

false

Closed early due to poor accrual.

[ "Insufficient_Enrollment", "Insufficient_Data" ]

false

true

false

Closed for lack of enrollment

[ "Insufficient_Enrollment" ]

false

true

false

Closed to Accrual

[ "Insufficient_Enrollment" ]

false

true

false

Closed to accrual in March 2009 for slow accrual.

[ "Business_Administrative", "Logistics_Resources" ]

false

true

false

true

false

Closed, never started."

[ "Invalid_Reason" ]

false

true

false

Closure of Indiana University Health Proton Center in December 2014

[ "Study_Staff_Moved" ]

false

true

false

Closures due to COVID-19

[ "Covid19" ]

false

true

false

CoStar Stent IDE failed to meet primary endpoint

[ "Negative" ]

false

true

false

Collaboration could not be established

[ "Business_Administrative" ]

false

true

false

Collaborator no longer interested, short of funds"

[ "Business_Administrative" ]

false

true

false

Collected study data was not usable due to process miscommunications

[ "Logistics_Resources" ]

false

true

false

Combination of departure of Investigator from one site and slow recruitment rate

[ "Insufficient_Enrollment" ]

false

true

false

Comflicting interim data

[ "Negative" ]

false

true

false